Iovance Biotherapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. 

CEO
Frederick G. Vogt
CEOFrederick G. Vogt
Employees
975
Employees975
Headquarters
San Carlos, California
HeadquartersSan Carlos, California
Founded
2007
Founded2007
Employees
975
Employees975

IOVA Key Statistics

Market cap
1.56B
Market cap1.56B
Price-Earnings ratio
-3.63
Price-Earnings ratio-3.63
Dividend yield
Dividend yield
Average volume
18.81M
Average volume18.81M
High today
$3.58
High today$3.58
Low today
$3.44
Low today$3.44
Open price
$3.51
Open price$3.51
Volume
2.21M
Volume2.21M
52 Week high
$5.63
52 Week high$5.63
52 Week low
$1.64
52 Week low$1.64

Stock Snapshot

The current Iovance Biotherapeutics(IOVA) stock price is $3.50, with a market capitalization of 1.56B. The stock trades at a price-to-earnings (P/E) ratio of -3.63.

As of 2026-05-18, Iovance Biotherapeutics(IOVA) stock has fluctuated between $3.44 and $3.58. The current price stands at $3.50, placing the stock +1.7% above today's low and -2.2% off the high.

Iovance Biotherapeutics(IOVA) shares are trading with a volume of 2.21M, against a daily average of 18.81M.

During the past year, Iovance Biotherapeutics(IOVA) stock moved between $1.64 at its lowest and $5.63 at its peak.

During the past year, Iovance Biotherapeutics(IOVA) stock moved between $1.64 at its lowest and $5.63 at its peak.

IOVA News

TipRanks 3d
Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth

Iovance Biotherapeutics (IOVA) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, shar...

Simply Wall St 3d
What Iovance Biotherapeutics's Amtagvi Momentum and Narrowing Losses Means For Shareholders

Iovance Biotherapeutics recently reported past first‑quarter 2026 results showing revenue of US$71.43 million versus US$49.32 million a year earlier, with net l...

What Iovance Biotherapeutics's Amtagvi Momentum and Narrowing Losses Means For Shareholders
Simply Wall St 5d
Evaluating Iovance Biotherapeutics After Q1 Results And Amtagvi Adoption Update

Iovance Biotherapeutics (IOVA) is back in focus after first quarter 2026 results showed revenue of US$71.43 million, a reduced net loss, and management commenta...

Evaluating Iovance Biotherapeutics After Q1 Results And Amtagvi Adoption Update

Analyst ratings

80%

of 10 ratings
Buy
80%
Hold
20%
Sell
0%

People also own

Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.